Dilruba Şahin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dilruba Şahin has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Hatice Uslu
Clinic of Nuclear Medicine, Istanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Kadikoy, Turkey
3 shared publications- Esra Arslan
Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey
2 shared publications Mehmet Tarık Tatoğlu
Clinic of Nuclear Medicine, Istanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Kadikoy, Turkey
2 shared publications- Ömer Faruk Şahin
Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital
2 shared publications - Burak Canitez
Department of Nuclear Medicine, Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Fahrettin Kerim Gökay 161, Kadıköy, 34722 İstanbul, Turkey
1 shared publication Burcu Esen Akkaş
Department of Nuclear Medicine, University of Health Sciences Türkiye, Çam and Sakura City Hospital, Istanbul, Türkiye
1 shared publication
Latest Publications
- 24 August 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Targeting Imaging Modality in the Diagnosis of Endometriosis: 68Ga-FAPI-04 PET/CT
Endometriosis is a chronic condition in reproductive-age women, and diagnosis can be delayed for 4–11 years due to nonspecific symptoms and limited imaging. This underscores the need for new methods to overcome these diagnostic challenges. Fibroblast activation protein, strongly expressed in the perilesional stroma of endometriotic lesions, is a promising PET target. We included 8 women who underwent 68 Ga-FAPI-04 PET/CT for cyclic pelvic or extrapelvic pain and solid nodular lesions, later histopathologically confirmed as endometriosis. In these patients, we showed the targeting diagnostic potential of FAPI PET/CT and endometriotic foci with high accuracy compared with other imaging methods.
- 24 August 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Targeting Imaging Modality in the Diagnosis of Endometriosis: 68Ga-FAPI-04 PET/CT
Endometriosis is a chronic condition in reproductive-age women, and diagnosis can be delayed for 4–11 years due to nonspecific symptoms and limited imaging. This underscores the need for new methods to overcome these diagnostic challenges. Fibroblast activation protein, strongly expressed in the perilesional stroma of endometriotic lesions, is a promising PET target. We included 8 women who underwent 68 Ga-FAPI-04 PET/CT for cyclic pelvic or extrapelvic pain and solid nodular lesions, later histopathologically confirmed as endometriosis. In these patients, we showed the targeting diagnostic potential of FAPI PET/CT and endometriotic foci with high accuracy compared with other imaging methods.
- 24 March 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (7) , e422-e430
Diagnostic Performance of 68Ga DOTA-Pentixafor PET/CT in Benign Functional Adrenal Cortical Lesions
Objective: This prospective study evaluated the diagnostic performance of 68 Ga DOTA-Pentixafor PET/CT in characterizing the functional properties and lateralization of aldosterone-producing and cortisol-producing adrenal cortical lesions. The contribution of Pentixafor PET/CT to diagnosis and treatment planning was assessed in comparison with CT, MRI, and 18 F-FDG PET/CT. Patients and Methods: Twenty-five patients with suspected benign functional adrenal cortical masses were included. All patients underwent whole-body imaging at 1 hour and delayed abdominal imaging at 2 hours following intravenous administration of 18 F-FDG and 68 Ga DOTA-Pentixafor. Lesion SUVmax, LCRSUVmax, and LLRSUVmax values were analyzed and correlated with laboratory parameters, other imaging modalities, and postoperative clinical and pathologic outcomes. Results: 68 Ga DOTA-Pentixafor PET/CT demonstrated distinct focal uptake relative to the contralateral adrenal gland and liver parenchyma in 6/6 (100%) patients with suspected PA, 5/18 (27.7%) with suspected CS, and 1/1 (100%) with suspected EAS. Among patients with focal uptake who underwent surgery, all PA (5/5) and all CS (5/5) cases were confirmed as adrenocortical adenomas, resulting in no false-positive findings (PPV 100%). However, due to 2 false-negative CS cases, pentixafor PET/CT demonstrated an overall sensitivity of 83.3%, specificity of 100%, and accuracy of 85.7%. Thresholds of SUVmax >15.11, LCRSUVmax >1.74, and LLRSUVmax >4.36 yielded sensitivities of 33.3%, 41.7%, and 41.7%, respectively, while maintaining 100% specificity. Clinical and biochemical improvement was observed in 100% (5/5) of operated PA patients and 100% (5/5) of operated CS patients. Follow-up of nonoperated patients is ongoing. Conclusion: 68 Ga DOTA-Pentixafor PET/CT is a valuable diagnostic and potentially therapeutic tool for benign functional adrenal cortical disorders such as PA, CS, and EAS, with the potential to establish a new standard in minimally invasive patient management.
- 24 March 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (7) , e422-e430
Diagnostic Performance of 68Ga DOTA-Pentixafor PET/CT in Benign Functional Adrenal Cortical Lesions
Objective: This prospective study evaluated the diagnostic performance of 68 Ga DOTA-Pentixafor PET/CT in characterizing the functional properties and lateralization of aldosterone-producing and cortisol-producing adrenal cortical lesions. The contribution of Pentixafor PET/CT to diagnosis and treatment planning was assessed in comparison with CT, MRI, and 18 F-FDG PET/CT. Patients and Methods: Twenty-five patients with suspected benign functional adrenal cortical masses were included. All patients underwent whole-body imaging at 1 hour and delayed abdominal imaging at 2 hours following intravenous administration of 18 F-FDG and 68 Ga DOTA-Pentixafor. Lesion SUVmax, LCRSUVmax, and LLRSUVmax values were analyzed and correlated with laboratory parameters, other imaging modalities, and postoperative clinical and pathologic outcomes. Results: 68 Ga DOTA-Pentixafor PET/CT demonstrated distinct focal uptake relative to the contralateral adrenal gland and liver parenchyma in 6/6 (100%) patients with suspected PA, 5/18 (27.7%) with suspected CS, and 1/1 (100%) with suspected EAS. Among patients with focal uptake who underwent surgery, all PA (5/5) and all CS (5/5) cases were confirmed as adrenocortical adenomas, resulting in no false-positive findings (PPV 100%). However, due to 2 false-negative CS cases, pentixafor PET/CT demonstrated an overall sensitivity of 83.3%, specificity of 100%, and accuracy of 85.7%. Thresholds of SUVmax >15.11, LCRSUVmax >1.74, and LLRSUVmax >4.36 yielded sensitivities of 33.3%, 41.7%, and 41.7%, respectively, while maintaining 100% specificity. Clinical and biochemical improvement was observed in 100% (5/5) of operated PA patients and 100% (5/5) of operated CS patients. Follow-up of nonoperated patients is ongoing. Conclusion: 68 Ga DOTA-Pentixafor PET/CT is a valuable diagnostic and potentially therapeutic tool for benign functional adrenal cortical disorders such as PA, CS, and EAS, with the potential to establish a new standard in minimally invasive patient management.
- 7 February 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 63, 102654
Physiological differences in bone uptake of [99mTc]Tc-pyrophosphate in men and women undergoing cardiac scintigraphy
- 7 February 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 63, 102654
Physiological differences in bone uptake of [99mTc]Tc-pyrophosphate in men and women undergoing cardiac scintigraphy
- 23 November 2024
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 39 (4) , 334-341
PRIMARY scoring in 68Ga-PSMA PET/CT: correlation with prostate cancer risk groups and its potential impact on active surveillance
Objective The PRIMARY scoring system is a scale designed to identify clinically significant intraprostatic malignancies on 68Ga-PSMA PET/CT images. Active surveillance is a management method for patients with low-risk prostate cancer. In this study, we aimed to assess the efficacy of PRIMARY scoring in identifying appropriate candidates for active surveillance based on the distribution within prostate cancer risk groups. Methods The data of 134 patients diagnosed with PCa by biopsy who underwent 68Ga-PSMA PET/CT imaging for post-diagnostic staging purposes were retrospectively analyzed. Age, total PSA, ISUP grade, prostate lesion SUVmax values, PI-RADS scores, and PRIMARY scores were recorded. Patients were classified into low-risk and intermediate/high-risk groups. Results In the intermediate/high-risk group, the PRIMARY score was 1–2 in 17.6% and 3–5 in 82.4% of patients. In the low-risk group, the PRIMARY score was 1–2 in 34.7% and 3–5 in 65.3% of patients. None of the patients in the low-risk group had a PRIMARY score of 5. The most frequent PRIMARY score in both groups was 4, and there was a significant difference between the average SUVmax values of the intermediate/high and low-risk groups with a PRIMARY score of 4 (p = 0.018). The sensitivity of PRIMARY scoring in detecting patients in the intermediate/high-risk group was 82.3%, the specificity was 34.6%, and the positive predictive value (PPV) was 68.6%. When a cut-off SUVmax value 5.0 was used for the PRIMARY score of 4, the sensitivity was 67.0%, the specificity was 65.3% and the PPV was 77.0%. In the ROC analysis, the area under the curve was 0.727 for PRIMARY scoring, 0.662 for PI-RADS, and 0.744 for their combined mean. Conclusion The PRIMARY scoring system can complement PI-RADS scoring in mpMRI for selecting patients suitable for active surveillance. Revising the PRIMARY score 4 with an SUVmax cut-off value may increase the specificity.
- 23 November 2024
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 39 (4) , 334-341
PRIMARY scoring in 68Ga-PSMA PET/CT: correlation with prostate cancer risk groups and its potential impact on active surveillance
Objective The PRIMARY scoring system is a scale designed to identify clinically significant intraprostatic malignancies on 68Ga-PSMA PET/CT images. Active surveillance is a management method for patients with low-risk prostate cancer. In this study, we aimed to assess the efficacy of PRIMARY scoring in identifying appropriate candidates for active surveillance based on the distribution within prostate cancer risk groups. Methods The data of 134 patients diagnosed with PCa by biopsy who underwent 68Ga-PSMA PET/CT imaging for post-diagnostic staging purposes were retrospectively analyzed. Age, total PSA, ISUP grade, prostate lesion SUVmax values, PI-RADS scores, and PRIMARY scores were recorded. Patients were classified into low-risk and intermediate/high-risk groups. Results In the intermediate/high-risk group, the PRIMARY score was 1–2 in 17.6% and 3–5 in 82.4% of patients. In the low-risk group, the PRIMARY score was 1–2 in 34.7% and 3–5 in 65.3% of patients. None of the patients in the low-risk group had a PRIMARY score of 5. The most frequent PRIMARY score in both groups was 4, and there was a significant difference between the average SUVmax values of the intermediate/high and low-risk groups with a PRIMARY score of 4 (p = 0.018). The sensitivity of PRIMARY scoring in detecting patients in the intermediate/high-risk group was 82.3%, the specificity was 34.6%, and the positive predictive value (PPV) was 68.6%. When a cut-off SUVmax value 5.0 was used for the PRIMARY score of 4, the sensitivity was 67.0%, the specificity was 65.3% and the PPV was 77.0%. In the ROC analysis, the area under the curve was 0.727 for PRIMARY scoring, 0.662 for PI-RADS, and 0.744 for their combined mean. Conclusion The PRIMARY scoring system can complement PI-RADS scoring in mpMRI for selecting patients suitable for active surveillance. Revising the PRIMARY score 4 with an SUVmax cut-off value may increase the specificity.
- Open Access
- 26 September 2024
- Published by Springer Nature in Research Square
PRIMARY Scoring in 68Ga-PSMA PET/CT: Correlation with Prostate Cancer Risk Groups and Its Potential Impact on Active Surveillance
Objective The PRIMARY scoring system is a scale designed to identify clinically significant intraprostatic malignancies on 68Ga-PSMA PET/CT images. Active surveillance is a management method for patients with low-risk prostate cancer. In this study, we aimed to assess the efficacy of PRIMARY scoring in identifying appropriate candidates for active surveillance based on the distribution within prostate cancer risk groups. Methods The data of 134 patients diagnosed with PCa by biopsy who underwent 68Ga-PSMA PET/CT imaging for post-diagnostic staging purposes were retrospectively analyzed. Age, total PSA, ISUP grade, prostate lesion SUVmax values, PI-RADS scores, and PRIMARY scores were recorded. Patients were classified into low-risk and intermediate/high-risk groups. Results In the intermediate/high-risk group, the PRIMARY score was 1–2 in 17.6% and 3–5 in 82.4% of patients. In the low-risk group, the PRIMARY score was 1–2 in 34.7% and 3–5 in 65.3% of patients. None of the patients in the low-risk group had a PRIMARY score of 5. The most frequent PRIMARY score in both groups was 4, and there was a significant difference between the average SUVmax values of the intermediate/high and low-risk groups with a PRIMARY score of 4 (p = 0.018). The sensitivity of PRIMARY scoring in detecting patients in the intermediate/high-risk group was 82.3%, the specificity was 34.6%, and the positive predictive value (PPV) was 68.6%. When a cut-off SUVmax value 5.0 was used for the PRIMARY score of 4, the sensitivity was 67.0%, the specificity was 65.3% and the PPV was 77.0%. In the ROC analysis, the area under the curve was 0.727 for PRIMARY scoring, 0.662 for PI-RADS, and 0.744 for their combined mean. Conclusion The PRIMARY scoring system can complement PI-RADS scoring in mpMRI for selecting patients suitable for active surveillance. Revising the PRIMARY score 4 with an SUVmax cut-off value may increase the specificity.
- 26 September 2024
- Published by Springer Nature in Research Square
Open AccessPRIMARY Scoring in 68Ga-PSMA PET/CT: Correlation with Prostate Cancer Risk Groups and Its Potential Impact on Active Surveillance
Objective The PRIMARY scoring system is a scale designed to identify clinically significant intraprostatic malignancies on 68Ga-PSMA PET/CT images. Active surveillance is a management method for patients with low-risk prostate cancer. In this study, we aimed to assess the efficacy of PRIMARY scoring in identifying appropriate candidates for active surveillance based on the distribution within prostate cancer risk groups. Methods The data of 134 patients diagnosed with PCa by biopsy who underwent 68Ga-PSMA PET/CT imaging for post-diagnostic staging purposes were retrospectively analyzed. Age, total PSA, ISUP grade, prostate lesion SUVmax values, PI-RADS scores, and PRIMARY scores were recorded. Patients were classified into low-risk and intermediate/high-risk groups. Results In the intermediate/high-risk group, the PRIMARY score was 1–2 in 17.6% and 3–5 in 82.4% of patients. In the low-risk group, the PRIMARY score was 1–2 in 34.7% and 3–5 in 65.3% of patients. None of the patients in the low-risk group had a PRIMARY score of 5. The most frequent PRIMARY score in both groups was 4, and there was a significant difference between the average SUVmax values of the intermediate/high and low-risk groups with a PRIMARY score of 4 (p = 0.018). The sensitivity of PRIMARY scoring in detecting patients in the intermediate/high-risk group was 82.3%, the specificity was 34.6%, and the positive predictive value (PPV) was 68.6%. When a cut-off SUVmax value 5.0 was used for the PRIMARY score of 4, the sensitivity was 67.0%, the specificity was 65.3% and the PPV was 77.0%. In the ROC analysis, the area under the curve was 0.727 for PRIMARY scoring, 0.662 for PI-RADS, and 0.744 for their combined mean. Conclusion The PRIMARY scoring system can complement PI-RADS scoring in mpMRI for selecting patients suitable for active surveillance. Revising the PRIMARY score 4 with an SUVmax cut-off value may increase the specificity.
- 14 March 2024
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 63 (06) , 369-370
Growing Teratoma Syndrome Revealed By F-18 FDG PET/CT
- 14 March 2024
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 63 (06) , 369-370
Growing Teratoma Syndrome Revealed By F-18 FDG PET/CT